Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
US Department of Justice
US Army
Boehringer Ingelheim
Chinese Patent Office

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,220,737

« Back to Dashboard

Title:Plant cell culture expressing human lysosomal proteins and uses thereof
Abstract: A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.
Inventor(s): Shaaltiel; Yoseph (Timrat, IL), Baum; Gideon (Kibbutz Ayelet HaShachar, IL), Bartfeld; Daniel (Moran, IL), Hashmueli; Sharon (Ramot-Naftali, IL), Lewkowicz; Ayala (Kfar-Vradim, IL)
Assignee: Protalix Ltd. (Carmiel, IL)
Filing Date:Jun 02, 2014
Application Number:14/292,966
Claims:1. A method of increasing hydrolysis of glycosphingolipid glucocerebroside in macrophages of a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of lyophilized plant cells expressing a recombinant human glucocerebrosidase protein comprising the amino acid sequence of SEQ ID NO: 15, thereby increasing hydrolysis of glycosphingolipid glucocerebroside in macrophages of the subject.

2. The method of claim 1, wherein said human glucocerebrosidase protein is glycosylated and comprises at least one exposed mannose, at least one fucose having an alpha (1-3) glycosidic bond and at least one xylose.

3. The method of claim 1, wherein said human glucocerebrosidase protein is linked at its N terminus to an endoplasmic reticulum signal peptide.

4. The method of claim 1, wherein said glucocerebrosidase protein has glucocerebrosidase catalytic activity.

5. The method of claim 1, wherein said plant cells are carrot cells from suspension culture.

6. The method of claim 1 wherein said plant cells are formulated in a pharmaceutical composition for treating Gaucher's disease comprising the plant cells and a pharmaceutically acceptable carrier.

7. The method of claim 6, wherein said pharmaceutical composition is formulated for oral administration.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Cantor Fitzgerald
Chinese Patent Office
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.